Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $92.00 → $73.00 | Outperform | Wedbush |
| 8/26/2024 | Outperform → Peer Perform | Wolfe Research | |
| 6/25/2024 | $104.00 | Outperform | Oppenheimer |
| 4/2/2024 | $62.00 | Neutral | Goldman |
| 2/15/2024 | $77.00 | Outperform | Wolfe Research |
| 12/8/2023 | $72.00 | Buy | Citigroup |
| 11/2/2023 | $74.00 | Buy | Stifel |
| 9/14/2023 | Buy → Neutral | Bryan Garnier |
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price target.
Oppenheimer analyst Andreas Argyrides initiates coverage on MoonLake (NASDAQ:MLTX) with a Outperform rating and announces Price Target of $104.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price target.
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026Strong market performance of other IL-17 inhibitors in hidradenitis suppurativa (HS) and other inflammatory indications validating large market opportunity for sonelokimabPhase 3 clinical program in HS is progressing as per plan with primary endpoint readout anticipated as of mid-2025Preparations for Phase 3 clinical program in psoriatic arthritis (PsA) completed with patient enrollmen
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in hidradenitis suppurativa ("HS"), with topline results anticipated as of mid-2025Secured positive feedback from both U.S. Food and Drug Administration ("FDA") and the E.U. European Medicines Agency ("EMA") on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in psoriatic arthritis ("PsA") and outlined the clinical plan with topline results anticipated in end-2026Ended the quarter with $519.8 million in cash, cash equivalents and short-term marketable debt securities, expected to
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in hidradenitis suppurativa (HS) and outlined the development plan with topline results anticipated in mid-2025Reported significant improvements observed across all key outcomes with sonelokimab over 24 weeks in the ARGO Phase 2 trial in active psoriatic arthritis (PsA) including unprecedented multi-domain responses across joints, skin and other domains, supporting potential best-in-class profile of sonelokimabAnnounced the imminent commencement of four additional
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026Strong market performance of other IL-17 inhibitors in hidradenitis suppurativa (HS) and other inflammatory indications validating large market opportunity for sonelokimabPhase 3 clinical program in HS is progressing as per plan with primary endpoint readout anticipated as of mid-2025Preparations for Phase 3 clinical program in psoriatic arthritis (PsA) completed with patient enrollmen
MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (("MoonLake", NASDAQ:MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from 2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CETThe event will provide business updates from MoonLake's CEO Jorge Santos da Silva, CSO Kristian Reich and CFO Matthias Bodenstedt and include details on the Phase 3 programs for our investigational Nanobody® sonelokimab (SLK) in hid
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in hidradenitis suppurativa ("HS"), with topline results anticipated as of mid-2025Secured positive feedback from both U.S. Food and Drug Administration ("FDA") and the E.U. European Medicines Agency ("EMA") on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in psoriatic arthritis ("PsA") and outlined the clinical plan with topline results anticipated in end-2026Ended the quarter with $519.8 million in cash, cash equivalents and short-term marketable debt securities, expected to
10-Q - MoonLake Immunotherapeutics (0001821586) (Filer)
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
8-K - MoonLake Immunotherapeutics (0001821586) (Filer)
Wedbush resumed coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $73.00 from $92.00 previously
Wolfe Research downgraded MoonLake Immunotherapeutics from Outperform to Peer Perform
Oppenheimer initiated coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $104.00
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
4 - MoonLake Immunotherapeutics (0001821586) (Issuer)
SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)
SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)